pharmaphorum3h
Starboard spells out its concerns with Pfizer's direction
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
What activist hedge fund Starboard wants from Pfizer
Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...
FiercePharma19h
UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.
Starboard Value CEO Jeff Smith: Pfizer needs to do a better job disciplining itself on investments
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...
Starboard says Kenvue's skin health segment weighing on performance
Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster ...
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
BioPharma Dive17h
Starboard makes case for change at Pfizer, citing research, M&A missteps
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
BioSpace20h
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
Starboard Focused on Kenvue's Struggling Unit
Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
Activist Starboard could push for Kenvue to sell some/all of its SHB business - analyst
Financial writer highlights activist investor Starboard Value's push for Kenvue (KVUE) to divest its challenged skin, ...